Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$4.7 million.

  • Zevra Therapeutics' Change in Accured Expenses fell 13792.76% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.0 million, marking a year-over-year decrease of 8532.92%. This contributed to the annual value of -$3.6 million for FY2024, which is 13232.7% down from last year.
  • Zevra Therapeutics' Change in Accured Expenses amounted to -$4.7 million in Q3 2025, which was down 13792.76% from -$4.0 million recorded in Q2 2025.
  • Zevra Therapeutics' Change in Accured Expenses' 5-year high stood at $7.0 million during Q4 2024, with a 5-year trough of -$7.3 million in Q1 2024.
  • For the 5-year period, Zevra Therapeutics' Change in Accured Expenses averaged around -$339421.1, with its median value being -$189000.0 (2021).
  • Per our database at Business Quant, Zevra Therapeutics' Change in Accured Expenses crashed by 41058.02% in 2021 and then surged by 88930.04% in 2023.
  • Zevra Therapeutics' Change in Accured Expenses (Quarter) stood at $778000.0 in 2021, then soared by 140.23% to $1.9 million in 2022, then soared by 206.58% to $5.7 million in 2023, then grew by 22.02% to $7.0 million in 2024, then tumbled by 167.65% to -$4.7 million in 2025.
  • Its last three reported values are -$4.7 million in Q3 2025, -$4.0 million for Q2 2025, and -$7.3 million during Q1 2025.